Aurora Cannabis (TSX:ACB; OTCQX:ACBFF) announced its financial and operational results for the fourth quarter and full fiscal year.
As quoted in the press release:

Q4 2017 Financial and Operational Highlights


  • Recorded $5.9 million in revenues, reflecting growth in patient numbers and an increase in the average price per gram of product sold, which now includes high margin cannabis oils.
  • Continued to progress on schedule and on budget with the construction of the Company’s Aurora Sky facility.
  • Completed the acquisition of Pedanios GmbH, Germany’s largest distributor of cannabis. This acquisition provides access to the single largest federally-legal medical cannabis market in the world, as well as a gateway to the rapidly-developing EU market. Increasing momentum in the EU towards the adoption of medical cannabis legislation has the potential to create a market of several hundred million people.
  • Completed the acquisition of Peloton Pharmaceuticals, a 40,000 square foot facility, which Aurora currently is completing, with first harvest anticipated shortly after calendar-year end.
  • Completed its cornerstone investment in the IPO of Cann Group Limited, Australia’s first licensed cannabis company, and now holds a 19.9% ownership stake.

Click here to read the full press release.

Source: www.newswire.ca

Partnership Aimed at Delivering Psychedelic
Capsule for Dosing Study in Human Clinical Trial

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, and Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, have met another early milestone in the development of an initial all natural psilocybin extract.

Keep reading... Show less

Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, and Numinus Wellness Inc. (“Numinus“) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, have met another early milestone in the development of an initial all natural psilocybin extract.

Optimi and Numinus, through Impact Clinical Trials Accelerator at the University of Calgary (“Impact”), have submitted a pre-clinical trial application to Health Canada for review and comment. Meanwhile, cultivation, research, formulation, and continuous validation studies to produce the investigational psilocybin extract for trial continue at the Health Canada-licensed Numinus lab in British Columbia, Canada.

Keep reading... Show less

Poised for Rapid Growth in Europe’s Largest Medical Cannabis Market

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) (“Curaleaf” or the “Company”) a leading international provider of consumer products in cannabis, today announced that wholly owned Curaleaf International subsidiary Adven GmbH (“Adven”) has launched its own range of medical cannabis products in Germany Europe’s largest medical cannabis market.  The initial launch of a high THC oil product aims to meet immediate patient demand and will be extended over the course of the year to incorporate a number of different strengths and THCCBD formulations in both oil and flower formats, addressing a wide range of patient needs. Germany is Europe’s largest medical cannabis market and is expected to be worth US$2.1 billion by 2025 1 .

Keep reading... Show less

After announcing placements of Fit Soda™ in well-known regional grocery chains such as HEB and Sprouts, Koios is pleased to announce that its Fit Soda™ functional beverage is now available in all Food Lion supermarkets, a chain which operates more than 1,100 grocery stores in the eastern United States. As the sugar-free beverage category continues to grow, Coca-Cola recently announced its prediction that its “Coke Zero Sugar” variety will be the firm’s biggest driver of growth in 2021 and beyond. Based on these industry trends, Koios’ objective is to strategically grow the market presence of Fit Soda™, which sold approximately 700,000 units in 2020, its first full calendar year on the market.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that as of Monday, May 10, 2021 all four flavours of Fit Soda ™ are being carried in more than 1,100 supermarkets operated by Food Lion LLC (“Food Lion”), a multistate grocery chain based in Salisbury, North Carolina. Since November 2020, the Company has placed its Fit Soda ™ functional beverage product with several other regional chains across the United States to include HEB (as announced in a November 4, 2020 press release), all three banners of Massachusetts-based Roche Bros. (as announced in a February 24, 2021 press release), and Sprouts Farmers Market (as announced in a March 4, 2021 press release). Approximately 700,000 units of Fit Soda ™ were sold during the product’s first full calendar year of retail sales in 2020 between retail placements in grocery and foodservice outlets, as well as direct-to-consumer sales through the Koios online store. With the addition of Fit Soda ™ to all 1,100 locations of Food Lion across ten U.S. states, the Company believes there is significant opportunity for Fit Soda ™ to have its best year yet in 2021.

Keep reading... Show less

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Harvest Health & Recreation Inc. (OTCQX: HRVSF) to Trulieve Cannabis Corp. is fair to Harvest Health shareholders. Under the terms of the agreement, Harvest shareholders will receive 0.1170 of a subordinate voting share of Trulieve for each Harvest subordinate voting share (or equivalent) held.

Halper Sadeh encourages Harvest Health shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com .

Keep reading... Show less